U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07732413) titled 'Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer' on July 20.
Brief Summary: This is a open label Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, in combination with temozolomide chemotherapy in children with primary brain tumors.
Study Start Date: Oct. 08, 2026
Study Type: INTERVENTIONAL
Condition:
Progressive Pediatric Brain Cancer
Intervention:
DRUG: NLG802 (indoximod Prodrug)
NLG802 will be taken by mouth twice dai...